Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Allergic Drug Reactions01:27

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions01:29

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A systematic review of artificial intelligence in radiotherapy associated cardiovascular toxicity.

Cardio-oncology (London, England)·2026
Same author

A Qualitative Analysis of Cancer Survivors' Experience in a Time-Restricted Eating vs Control Clinical Trial to Address Cancer-Related Fatigue.

Seminars in oncology nursing·2026
Same author

Pharmacokinetics of venetoclax in a patient after whipple pancreaticoduodenectomy.

Cancer chemotherapy and pharmacology·2026
Same author

Artificial Intelligence and Machine Learning in Sexual Health and Dysfunction Across the Cancer Care Continuum: A Systematic Review.

Cancers·2025
Same author

Conflating polycythemia vera with essential thrombocytosis.

Blood advances·2025
Same author

Time-restricted eating to address persistent cancer-related fatigue among cancer survivors: a randomized controlled trial.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2025

Related Experiment Videos

Anagrelide: 20 years later.

Ashkan Emadi1, Jerry L Spivak

  • 1Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD 21231, USA.

Expert Review of Anticancer Therapy
|December 25, 2008
PubMed
Summary
This summary is machine-generated.

Thrombocytosis in myeloproliferative disorders (MPD) can cause clots. While lowering platelet counts helps microvascular events, anagrelide is a preferred, less myelotoxic option for treatment when needed.

Related Experiment Videos

Area of Science:

  • Hematology
  • Oncology

Background:

  • Thrombocytosis is a common characteristic of myeloproliferative disorders (MPD).
  • It can lead to vaso-occlusive symptoms or thrombosis, yet platelet count doesn't always correlate with these events.
  • Asymptomatic thrombocytosis in young MPD patients without cardiovascular risk factors typically does not require treatment.

Purpose of the Study:

  • To review the management of elevated platelet counts in MPD.
  • To discuss the pharmacology of anagrelide and its role as a first-line treatment.
  • To examine the differential diagnosis of thrombocytosis and thrombopoiesis physiology.

Main Methods:

  • Review of existing literature on thrombocytosis management in MPD.
  • Analysis of treatment options including hydroxyurea and anagrelide.
  • Discussion of drug safety profiles and long-term monitoring requirements.

Main Results:

  • Lowering platelet counts reduces microvascular events in MPD patients.
  • Hydroxyurea is effective for transient ischemic attacks but has limitations for venous thrombosis and long-term safety.
  • Anagrelide is considered a suitable first-line agent due to its lower myelotoxicity, though long-term safety requires monitoring.

Conclusions:

  • When platelet count reduction is necessary for MPD-associated thrombocytosis, anagrelide is a preferred first-line agent due to its safety profile.
  • Ongoing safety monitoring for anagrelide is essential, particularly for cardiovascular events and acute leukemia.
  • Further research into the long-term efficacy and safety of treatments for MPD-associated thrombocytosis is warranted.